Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
White Paper
January 18, 2016

Personalizing oncology with genomics

Next-generation sequencing will transform oncology clinical trials and treatments for cancer
How is next generation sequencing (NGS) transforming oncology clinical development and treatments for cancer? Read this recent white paper to learn how.

The overall goal in the era of emerging precision is to develop cancer medications that attack the right target, or targets, in the right disease, in the right patient, at the right dose to obtain the desired outcome. Several targeted therapies have successfully been developed and the pipeline of additional precision medicines looks promising. But how can the drug development community better capitalize on sophisticated genomics-based tools available to help transform clinical development and cancer care in the coming decade? This paper investigates fundamentals and key considerations to integrating NGS in the clinical development of oncology precision medicine.

Related Services:
Genomics enhances Clinical Immuno-oncology Trials

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Read More